

SAFETY DATA SHEET

▶ MVP Total RNA - Human K-562 Cells with and without PMA treatment, Part Number 540115

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : MVP Total RNA - Human K-562 Cells with and without PMA treatment, Part Number 540115

Part No. (Kit) : 540115

Part No. : MVP Total RNA, Human 540103-41
K-562 Cells
MVP Total RNA, Human 540099-41
K-562 Cells, PMA-Treated

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses	
Analytical reagent.	
MVP Total RNA, Human K-562 Cells	0.028 ml
MVP Total RNA, Human K-562 Cells, PMA-Treated	0.023 ml

1.3 Details of the supplier of the safety data sheet

Agilent Technologies Manufacturing GmbH & Co. KG
Hewlett-Packard-Str. 8
76337 Waldbronn
Germany
0800 603 1000

e-mail address of person responsible for this SDS : pdl-msds_author@agilent.com

1.4 Emergency telephone number

Emergency telephone number (with hours of operation) : CHEMTREC®: +(44)-870-8200418

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : MVP Total RNA, Human Mixture
K-562 Cells
MVP Total RNA, Human Mixture
K-562 Cells, PMA-Treated

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

Classification according to Directive 1999/45/EC [DPD]

MVP Total RNA, Human K-562 Cells The product is not classified as dangerous according to Directive 1999/45/EC and its amendments.

MVP Total RNA, Human K-562 Cells, PMA-Treated The product is not classified as dangerous according to Directive 1999/45/EC and its amendments.

Classification : MVP Total RNA, Human Not classified.
K-562 Cells
MVP Total RNA, Human Not classified.
K-562 Cells, PMA-Treated

Date of issue/Date of revision : 01/09/2015

SECTION 2: Hazards identification

See Section 16 for the full text of the R phrases or H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Signal word	: MVP Total RNA, Human K-562 Cells	No signal word.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	No signal word.
Hazard statements	: MVP Total RNA, Human K-562 Cells	No known significant effects or critical hazards.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	No known significant effects or critical hazards.

Precautionary statements

Prevention	: MVP Total RNA, Human K-562 Cells	Not applicable.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not applicable.

Response	: MVP Total RNA, Human K-562 Cells	Not applicable.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not applicable.

Storage	: MVP Total RNA, Human K-562 Cells	Not applicable.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not applicable.

Disposal	: MVP Total RNA, Human K-562 Cells	Not applicable.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not applicable.

Hazardous ingredients : No hazardous ingredient

Supplemental label elements	: MVP Total RNA, Human K-562 Cells	Not applicable.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not applicable.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles : Not applicable.

Special packaging requirements

Tactile warning of danger	: MVP Total RNA, Human K-562 Cells	Not applicable.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not applicable.

2.3 Other hazards

SECTION 2: Hazards identification

Other hazards which do not result in classification : MVP Total RNA, Human K-562 Cells None known.
 MVP Total RNA, Human K-562 Cells, PMA-Treated None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures : MVP Total RNA, Human K-562 Cells Mixture
 MVP Total RNA, Human K-562 Cells, PMA-Treated Mixture

Product/ingredient name

No hazardous ingredient

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs or vPvBs or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII
- [4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII
- [5] Substance of equivalent concern

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact	: MVP Total RNA, Human K-562 Cells	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
Inhalation	: MVP Total RNA, Human K-562 Cells	Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
Skin contact	: MVP Total RNA, Human K-562 Cells	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
Ingestion	: MVP Total RNA, Human K-562 Cells	Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

SECTION 4: First aid measures

Protection of first-aiders	: MVP Total RNA, Human K-562 Cells	No action shall be taken involving any personal risk or without suitable training.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	No action shall be taken involving any personal risk or without suitable training.

4.2 Most important symptoms and effects, both acute and delayed**Potential acute health effects**

Eye contact	: MVP Total RNA, Human K-562 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	No known significant effects or critical hazards.
Inhalation	: MVP Total RNA, Human K-562 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	No known significant effects or critical hazards.
Skin contact	: MVP Total RNA, Human K-562 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	No known significant effects or critical hazards.
Ingestion	: MVP Total RNA, Human K-562 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	No known significant effects or critical hazards.

Over-exposure signs/symptoms

Eye contact	: MVP Total RNA, Human K-562 Cells	No specific data.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	No specific data.
Inhalation	: MVP Total RNA, Human K-562 Cells	No specific data.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	No specific data.
Skin contact	: MVP Total RNA, Human K-562 Cells	No specific data.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	No specific data.
Ingestion	: MVP Total RNA, Human K-562 Cells	No specific data.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	: MVP Total RNA, Human K-562 Cells	Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.

SECTION 4: First aid measures

Specific treatments	: MVP Total RNA, Human K-562 Cells	No specific treatment.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	No specific treatment.

SECTION 5: Firefighting measures**5.1 Extinguishing media**

Suitable extinguishing media	: MVP Total RNA, Human K-562 Cells	Use an extinguishing agent suitable for the surrounding fire.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Use an extinguishing agent suitable for the surrounding fire.
Unsuitable extinguishing media	: MVP Total RNA, Human K-562 Cells	None known.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	None known.

5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture	: MVP Total RNA, Human K-562 Cells	In a fire or if heated, a pressure increase will occur and the container may burst.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	In a fire or if heated, a pressure increase will occur and the container may burst.
Hazardous combustion products	: MVP Total RNA, Human K-562 Cells	No specific data.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	No specific data.

5.3 Advice for firefighters

Special precautions for fire-fighters	: MVP Total RNA, Human K-562 Cells	Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
Special protective equipment for fire-fighters	: MVP Total RNA, Human K-562 Cells	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

For non-emergency personnel	: MVP Total RNA, Human K-562 Cells	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.
	MVP Total RNA, Human K-562 Cells, PMA-	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas.

SECTION 6: Accidental release measures

	Treated	Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.
For emergency responders	: MVP Total RNA, Human K-562 Cells	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
	MVP Total RNA, Human K-562 Cells, PMA-Treated	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	: MVP Total RNA, Human K-562 Cells	Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
6.3 Methods and material for containment and cleaning up		
Methods for cleaning up	: MVP Total RNA, Human K-562 Cells	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
6.4 Reference to other sections	: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.	

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Protective measures	: MVP Total RNA, Human K-562 Cells	Put on appropriate personal protective equipment (see Section 8).
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Put on appropriate personal protective equipment (see Section 8).
Advice on general occupational hygiene	: MVP Total RNA, Human K-562 Cells	Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

SECTION 7: Handling and storage

7.2 Conditions for safe storage, including any incompatibilities	: MVP Total RNA, Human K-562 Cells	Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.
7.3 Specific end use(s)		
Recommendations	: MVP Total RNA, Human K-562 Cells	Industrial applications.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Industrial applications.
Industrial sector specific solutions	: MVP Total RNA, Human K-562 Cells	Not applicable.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not applicable.

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits

No exposure limit value known.

Recommended monitoring procedures

: If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

No DNELs available.

PNECs

No PNECs available.

8.2 Exposure controls

Appropriate engineering controls : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Individual protection measures

SECTION 8: Exposure controls/personal protection

- Hygiene measures** : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
- Eye/face protection** : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.
- Skin protection**
- Hand protection** : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.
- Body protection** : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Respiratory protection** : Use a properly fitted, air-purifying or air-fed respirator complying with an approved standard if a risk assessment indicates this is necessary. Respirator selection must be based on known or anticipated exposure levels, the hazards of the product and the safe working limits of the selected respirator.
- Environmental exposure controls** : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties****Appearance**

- Physical state** : MVP Total RNA, Liquid.
Human K-562 Cells
MVP Total RNA, Liquid.
Human K-562 Cells,
PMA-Treated
- Colour** : MVP Total RNA, Not available.
Human K-562 Cells
MVP Total RNA, Not available.
Human K-562 Cells,
PMA-Treated
- Odour** : MVP Total RNA, Not available.
Human K-562 Cells
MVP Total RNA, Not available.
Human K-562 Cells,
PMA-Treated
- Odour threshold** : MVP Total RNA, Not available.
Human K-562 Cells
MVP Total RNA, Not available.
Human K-562 Cells,
PMA-Treated
- pH** : MVP Total RNA, 8
Human K-562 Cells
MVP Total RNA, 8
Human K-562 Cells,
PMA-Treated

SECTION 9: Physical and chemical properties

Melting point/freezing point	: MVP Total RNA, Human K-562 Cells	0°C
	MVP Total RNA, Human K-562 Cells, PMA-Treated	0°C
Initial boiling point and boiling range	: MVP Total RNA, Human K-562 Cells	100°C
	MVP Total RNA, Human K-562 Cells, PMA-Treated	100°C
Flash point	: MVP Total RNA, Human K-562 Cells	Not available.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.
Evaporation rate	: MVP Total RNA, Human K-562 Cells	Not available.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.
Flammability (solid, gas)	: MVP Total RNA, Human K-562 Cells	Not applicable.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not applicable.
Upper/lower flammability or explosive limits	: MVP Total RNA, Human K-562 Cells	Not available.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.
Vapour pressure	: MVP Total RNA, Human K-562 Cells	Not available.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.
Vapour density	: MVP Total RNA, Human K-562 Cells	Not available.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.
Relative density	: MVP Total RNA, Human K-562 Cells	Not available.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.
Solubility(ies)	: MVP Total RNA, Human K-562 Cells	Easily soluble in the following materials: cold water and hot water.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Easily soluble in the following materials: cold water and hot water.
Partition coefficient: n-octanol/water	: MVP Total RNA, Human K-562 Cells	Not available.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.
Auto-ignition temperature	: MVP Total RNA, Human K-562 Cells	Not available.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.

SECTION 9: Physical and chemical properties

Decomposition temperature	: MVP Total RNA, Human K-562 Cells	Not available.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.
Viscosity	: MVP Total RNA, Human K-562 Cells	Not available.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.
Explosive properties	: MVP Total RNA, Human K-562 Cells	Not available.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.
Oxidising properties	: MVP Total RNA, Human K-562 Cells	Not available.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.

9.2 Other information

No additional information.

SECTION 10: Stability and reactivity

10.1 Reactivity	: MVP Total RNA, Human K-562 Cells	No specific test data related to reactivity available for this product or its ingredients.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	: MVP Total RNA, Human K-562 Cells	The product is stable.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	The product is stable.
10.3 Possibility of hazardous reactions	: MVP Total RNA, Human K-562 Cells	Under normal conditions of storage and use, hazardous reactions will not occur.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	: MVP Total RNA, Human K-562 Cells	No specific data.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	No specific data.
10.5 Incompatible materials	: MVP Total RNA, Human K-562 Cells	May react or be incompatible with oxidising materials.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	May react or be incompatible with oxidising materials.
10.6 Hazardous decomposition products	: MVP Total RNA, Human K-562 Cells	Under normal conditions of storage and use, hazardous decomposition products should not be produced.
	: MVP Total RNA, Human K-562 Cells, PMA-Treated	Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information**11.1 Information on toxicological effects****Acute toxicity**

Not available.

Acute toxicity estimates

Not available.

Irritation/Corrosion**Conclusion/Summary** : Not available.**Sensitiser****Conclusion/Summary** : Not available.**Chronic toxicity / Carcinogenicity / Mutagenicity / Teratogenicity / Reproductive toxicity**

Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on the likely routes of exposure : MVP Total RNA, Human K-562 Cells Not available.
MVP Total RNA, Human K-562 Cells, PMA-Treated Not available.

Potential acute health effects

Inhalation : MVP Total RNA, Human K-562 Cells No known significant effects or critical hazards.
MVP Total RNA, Human K-562 Cells, PMA-Treated No known significant effects or critical hazards.

Ingestion : MVP Total RNA, Human K-562 Cells No known significant effects or critical hazards.
MVP Total RNA, Human K-562 Cells, PMA-Treated No known significant effects or critical hazards.

Skin contact : MVP Total RNA, Human K-562 Cells No known significant effects or critical hazards.
MVP Total RNA, Human K-562 Cells, PMA-Treated No known significant effects or critical hazards.

Eye contact : MVP Total RNA, Human K-562 Cells No known significant effects or critical hazards.
MVP Total RNA, Human K-562 Cells, PMA-Treated No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Inhalation : MVP Total RNA, Human K-562 Cells No specific data.
MVP Total RNA, Human K-562 Cells, PMA-Treated No specific data.

Ingestion : MVP Total RNA, Human K-562 Cells No specific data.
MVP Total RNA, Human K-562 Cells, PMA-Treated No specific data.

SECTION 11: Toxicological information

Skin contact	: MVP Total RNA, Human K-562 Cells	No specific data.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	No specific data.
Eye contact	: MVP Total RNA, Human K-562 Cells	No specific data.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	No specific data.

Delayed and immediate effects and also chronic effects from short and long term exposure**Short term exposure**

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Long term exposure

Potential immediate effects : Not available.

Potential delayed effects : Not available.

Potential chronic health effects

General	: MVP Total RNA, Human K-562 Cells	No known significant effects or critical hazards.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	No known significant effects or critical hazards.
Carcinogenicity	: MVP Total RNA, Human K-562 Cells	No known significant effects or critical hazards.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	No known significant effects or critical hazards.
Mutagenicity	: MVP Total RNA, Human K-562 Cells	No known significant effects or critical hazards.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	No known significant effects or critical hazards.
Teratogenicity	: MVP Total RNA, Human K-562 Cells	No known significant effects or critical hazards.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	No known significant effects or critical hazards.
Developmental effects	: MVP Total RNA, Human K-562 Cells	No known significant effects or critical hazards.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	No known significant effects or critical hazards.
Fertility effects	: MVP Total RNA, Human K-562 Cells	No known significant effects or critical hazards.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	No known significant effects or critical hazards.

Toxicokinetics

Absorption	: MVP Total RNA, Human K-562 Cells	Not available.
	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.

SECTION 11: Toxicological information

Distribution	:	MVP Total RNA, Human K-562 Cells	Not available.
	:	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.
Metabolism	:	MVP Total RNA, Human K-562 Cells	Not available.
	:	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.
Elimination	:	MVP Total RNA, Human K-562 Cells	Not available.
	:	MVP Total RNA, Human K-562 Cells, PMA-Treated	Not available.
Other information	:	Not available.	

SECTION 12: Ecological information**12.1 Toxicity**

Conclusion/Summary : Not available.

12.2 Persistence and degradability

Conclusion/Summary : Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

Soil/water partition coefficient (K_{oc}) : Not available.

Mobility : Not available.

12.5 Results of PBT and vPvB assessment

PBT : Not applicable.

vPvB : Not applicable.

12.6 Other adverse effects : No known significant effects or critical hazards.

SECTION 13: Disposal considerations**13.1 Waste treatment methods****Product**

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous waste : Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 91/689/EEC.

Packaging

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

SECTION 13: Disposal considerations

Special precautions : This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

Regulatory information

ADR/RID / IMDG / IATA : Not regulated.

14.6 Special precautions for user : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code : Not available.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles : Not applicable.

Other EU regulations

Europe inventory : All components are listed or exempted.

Seveso Directive

This product is not controlled under the Seveso Directive.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol (Annexes A, B, C, E)

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Inform Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

International lists

National inventory

Australia : All components are listed or exempted.

Canada : All components are listed or exempted.

China : All components are listed or exempted.

Date of issue/Date of revision : 01/09/2015

SECTION 15: Regulatory information

- Japan** : All components are listed or exempted.
- Malaysia** : Not determined.
- New Zealand** : All components are listed or exempted.
- Philippines** : All components are listed or exempted.
- Republic of Korea** : All components are listed or exempted.
- Taiwan** : All components are listed or exempted.
- United States** : All components are listed or exempted.

15.2 Chemical Safety Assessment : This product contains substances for which Chemical Safety Assessments might still be required.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms : ATE = Acute Toxicity Estimate
 CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]
 DNEL = Derived No Effect Level
 EUH statement = CLP-specific Hazard statement
 PNEC = Predicted No Effect Concentration
 RRN = REACH Registration Number

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Not classified.	

Date of issue/ Date of revision : 01/09/2015

Date of previous issue : 17/05/2013.

Version : 2.01

Notice to reader

Disclaimer: The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.